Publication | Closed Access

PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial

MedicineClinical TrialsGynecologyPharmacotherapyCancer TreatmentPaola-1/engot-ov25 TrialOncologyRadiation OncologyLeuven Hrd TestGynecology OncologyEndocrine-related CancerOvarian Cancer PatientsOvarian CancerHealth Sciences